Spero Therapeutics, Inc. (SPRO)
$
2.13
-0.22 (-10.33%)
Key metrics
Financial statements
Free cash flow per share
-0.6029
Market cap
38.1 Million
Price to sales ratio
1.0984
Debt to equity
0.1171
Current ratio
2.5626
Income quality
0.4785
Average inventory
0
ROE
-0.9896
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to identifying, developing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company showcases a strong financial performance, as evidenced by its net income ratio of -2.50 reflecting the company's profitability margin. Additionally, the income before tax ratio stands at -2.50 highlighting the pre-tax margin associated with its operations. The total costs and expenses for the company amount to $100,757,000.00 which underscores its overall spending. Among its product candidates are tebipenem pivoxil hydrobromide (HBr), intended for complicated urinary tract infections including pyelonephritis in adults, SPR206, an IV-administered agent aimed at treating MDR Gram-negative bacterial infections in hospital settings, and SPR720, an oral antibiotic for non-tuberculous mycobacterial pulmonary disease. The diluted EPS is -$1.27 accounting for potential share dilution, while the company reports an EBITDA of -$73,361,000.00 a key indicator of its operational profitability. Spero has established several collaborations, including license agreements with Meiji Seika Pharma Co., Ltd. for the development of tebipenem HBr, and with Everest Medicines for the commercialization of SPR206 in Greater China, South Korea, and Southeast Asia. Furthermore, it collaborates with the Bill & Melinda Gates Medical Research Institute for the development of SPR720 against Mycobacterium tuberculosis, and holds a patent agreement with Vertex Pharmaceuticals Incorporated concerning SPR720 and SPR719, its active metabolite. In terms of market positioning, the stock is affordable at $2.13 catering to budget-conscious investors. However, it has a low average trading volume of 3,204,917.00 indicating lower market activity around its shares. With a market capitalization of $119,089,578.00 the company is classified as a small-cap player in the healthcare market. Spero Therapeutics is a key player in the pharmaceutical industry, driving innovation and contributing significantly to the overall market landscape. It belongs to the Healthcare sector, where it continues to push the boundaries of treatment options for conditions that are challenging to manage, thus enhancing the prospects for patients undergoing therapy.
Is Spero Therapeutics, Inc. (SPRO) a good investment?
Investing in Spero Therapeutics, Inc. (SPRO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Spero Therapeutics, Inc. (SPRO)'s stock forecast?
Analysts predict Spero Therapeutics, Inc. stock to fluctuate between $0.51 (low) and $2.48 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Spero Therapeutics, Inc.'s market capitalization?
As of 2025-05-29, Spero Therapeutics, Inc.'s market cap is $119,089,578, based on 55,910,600 outstanding shares.
How does Spero Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Spero Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Spero Therapeutics, Inc. pay dividends?
Spero Therapeutics, Inc. pays dividends. The current dividend yield is 0.52%, with a payout of $0.02 per share.
How can I buy Spero Therapeutics, Inc. (SPRO) stock?
To buy Spero Therapeutics, Inc. (SPRO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SPRO. Place an order (Market, Limit, etc.).
What is the best time to invest in Spero Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Spero Therapeutics, Inc. perform in the last earnings report?
Revenue: $27,396,000 | EPS: -$1.27 | Growth: -395.35%.
Where can I find Spero Therapeutics, Inc.'s investor relations reports?
Visit https://sperotherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Spero Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Spero Therapeutics, Inc. stock?
All-time high: $22.24 (2021-02-08) | All-time low: $0.51 (2025-04-09).
What are the key trends affecting Spero Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
a day ago
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
benzinga.com
2 days ago
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.
globenewswire.com
2 days ago
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US 1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs 2 Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, met its primary endpoint and will stop early for efficacy (NCT06059846).3 The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial.
zacks.com
17 days ago
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.24 per share a year ago.
globenewswire.com
17 days ago
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
globenewswire.com
25 days ago
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close.
globenewswire.com
a month ago
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since November 2023. She will continue to serve as the Company's Chief Financial Officer and Treasurer.
seekingalpha.com
2 months ago
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief Executive Officer, Chief Financial Officer Tim Keutzer - Chief Operating Officer Conference Call Participants Gavin Clarke-Gartner - Evercore ISI Athena Chin - TD Cowen Operator Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in listen-only-mode.
zacks.com
2 months ago
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $0.96 per share a year ago.
globenewswire.com
2 months ago
CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
See all news
